Drug Profile
Anagrelide controlled release - Sellas Life Sciences Group
Alternative Names: Anagrelide CR - Sellas Life Sciences Group; CR anagrelide - Sellas Life Sciences Group; GALE-401Latest Information Update: 21 Nov 2021
Price :
$50
*
At a glance
- Originator BioVascular
- Developer Sellas Life Sciences Group
- Class 3-ring heterocyclic compounds; Antiplatelets; Antithrombotics; Imidazoles; Quinazolines; Small molecules
- Mechanism of Action Fibrinolytic agents; Type 3 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chronic myeloid leukaemia; Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
Most Recent Events
- 01 Dec 2019 Discontinued - Phase-II for Chronic myeloid leukaemia in USA (PO) (9287650; 3464169)
- 01 Dec 2019 Discontinued - Phase-II for Myelofibrosis in USA (PO) (9287650; 3464169)
- 01 Dec 2019 Discontinued - Phase-II for Polycythaemia vera in USA (PO) (9287650; 3464169)